Xeris Biopharma Holdings, Inc. (XERS) Ownership
XERS ownership summary
as of October 17, 2026- Institutions
- 60.6% of shares outstanding
- Insiders
- 3.03% of shares outstanding
- Shares outstanding
- 182.3M
- Float
- 176.1M shares available to trade
- Short interest
- 4.08% 7.2M shares short
- Days to cover
- 2.45 short interest down 10.6% vs prior month
- Institutions 60.63%
- Insiders 3.03%
- Other investors 36.34%
XERS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 7.97% | 14.5M | $149.8M | +1.6M (+12.2%) | June 30, 2026 |
| 2 | D. E. Shaw & Co LP | 4.28% | 7.8M | $80.5M | +15,947 (+0.2%) | June 30, 2026 |
| 3 | Vanguard Capital Management, LLC | 4.03% | 7.3M | $75.7M | +359,347 (+5.1%) | June 30, 2026 |
| 4 | State Street Corp | 2.64% | 4.8M | $49.7M | +163,392 (+3.5%) | June 30, 2026 |
| 5 | Geode Capital Management, LLC | 2.59% | 4.7M | $48.6M | +427,554 (+10.0%) | June 30, 2026 |
| 6 | Nuveen, LLC | 2.41% | 4.4M | $45.2M | +1.5M (+50.4%) | June 30, 2026 |
| 7 | Rosalind Advisors, Inc. | 1.60% | 2.9M | $30.0M | −322,719 (−10.0%) | June 30, 2026 |
| 8 | Qube Research & Technologies | 1.59% | 2.9M | $29.8M | −1.2M (−29.7%) | June 30, 2026 |
| 9 | Vanguard Portfolio Management, LLC | 1.44% | 2.6M | $27.1M | −39,400 (−1.5%) | June 30, 2026 |
| 10 | Wellington Management Company LLP | 1.30% | 2.4M | $24.4M | +193,749 (+8.9%) | June 30, 2026 |
| 11 | Morgan Stanley - Brokerage Accounts | 1.28% | 2.3M | $24.1M | −235,558 (−9.2%) | June 30, 2026 |
| 12 | Legal & General Group PLC | 1.10% | 2.0M | $20.8M | +104,503 (+5.5%) | June 30, 2026 |
| 13 | Armistice Capital, LLC | 1.07% | 2.0M | $20.2M | +48,864 (+2.6%) | June 30, 2026 |
| 14 | Two Sigma Investments LLC | 1.03% | 1.9M | $19.4M | −38,699 (−2.0%) | June 30, 2026 |
| 15 | Parkman Healthcare Partners LLC | 0.99% | 1.8M | $18.6M | +86,357 (+5.0%) | June 30, 2026 |
| 16 | Algert Global LLC | 0.96% | 1.7M | $18.0M | +585,984 (+50.6%) | June 30, 2026 |
| 17 | Northern Trust Corp | 0.88% | 1.6M | $16.5M | +153,132 (+10.6%) | June 30, 2026 |
| 18 | The Goldman Sachs Group Inc | 0.87% | 1.6M | $16.4M | −19,578 (−1.2%) | June 30, 2026 |
| 19 | AQR Capital Management LLC | 0.85% | 1.5M | $15.9M | +146,609 (+10.5%) | June 30, 2026 |
| 20 | Charles Schwab Investment Management Inc | 0.82% | 1.5M | $15.4M | +132,710 (+9.8%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 14 holders added 5.5M shares and 6 cut 1.9M.
XERS top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.85% | 5.2M | $53.5M | — | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 2.42% | 4.4M | $45.5M | −50,880 (−1.1%) | September 30, 2026 |
| 3 | CREF Total Global Stock Account R3 | 1.12% | 2.1M | $21.1M | +98,908 (+5.1%) | July 31, 2026 |
| 4 | Fidelity Small Cap Index | 1.02% | 1.9M | $19.3M | +18,158 (+1.0%) | July 31, 2026 |
| 5 | iShares Russell 2000 Growth ETF | 0.88% | 1.6M | $16.5M | −2,020 (−0.1%) | September 30, 2026 |
| 6 | State Street® SPDR® S&P® PhrmctlsETF | 0.74% | 1.4M | $13.9M | −16,786 (−1.2%) | September 30, 2026 |
| 7 | Nuveen Quant Small Cap Equity R6 | 0.66% | 1.2M | $12.4M | — | August 31, 2026 |
| 8 | Vanguard Russell 2000 ETF | 0.54% | 986K | $10.2M | +23,724 (+2.5%) | August 31, 2026 |
| 9 | First Trust Small Cap Gr AlphaDEX® ETF | 0.53% | 972K | $10.0M | +1,716 (+0.2%) | September 30, 2026 |
| 10 | Schwab US Small-Cap ETF™ | 0.53% | 966K | $10.0M | +648 (+0.1%) | September 30, 2026 |
| 11 | Fidelity Enhanced Small Cap Core ETF | 0.50% | 920K | $9.5M | +1,929 (+0.2%) | September 30, 2026 |
| 12 | Fidelity Extended Market Index | 0.47% | 855K | $8.8M | −13,366 (−1.5%) | August 31, 2026 |
| 13 | Nuveen Quant Small/Mid Cap Eq R6 | 0.44% | 797K | $8.2M | — | August 31, 2026 |
| 14 | iShares US Pharmaceuticals ETF | 0.37% | 666K | $6.9M | +2,049 (+0.3%) | September 30, 2026 |
| 15 | Federated Hermes MDT Small Cap Core IS | 0.34% | 616K | $6.3M | +383,084 (+164.6%) | June 30, 2026 |
| 16 | Janus Henderson Small/Md Cp Gr Alpha ETF | 0.30% | 542K | $5.6M | −105,118 (−16.2%) | September 30, 2026 |
| 17 | iShares Micro-Cap ETF | 0.30% | 541K | $5.6M | −3,728 (−0.7%) | September 30, 2026 |
| 18 | Vanguard Health Care ETF | 0.28% | 515K | $5.3M | +2,232 (+0.4%) | August 31, 2026 |
| 19 | Vanguard Explorer Inv | 0.27% | 490K | $5.1M | — | June 30, 2026 |
| 20 | Xtrackers S&P 500 Swap ETF 1C | 0.26% | 465K | $4.8M | −643,048 (−58.0%) | December 31, 2025 |
Funds report holdings monthly or quarterly; dates differ by fund.
XERS insider transactions
latest 17| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | Beth Hecht | Sell | $5.99 | 16,667 | $99,835 |
| 2026-03-30 | James Aloysius Brady | Sell | $5.54 | 10,834 | $60,020 |
| 2026-03-02 | Beth Hecht | Sell | $6.25 | 16,667 | $104,169 |
| 2026-02-02 | Beth Hecht | Sell | $7.45 | 16,667 | $124,169 |
| 2026-01-08 | Kevin Mcculloch | Sell | $8.00 | 15,000 | $120,000 |
| 2026-01-05 | John Patrick Shannon Jr | Sell | $7.08 | 24,907 | $176,342 |
| 2026-01-02 | Beth Hecht | Sell | $7.43 | 16,667 | $123,836 |
| 2025-12-19 | John Johnson | Sell | $7.22 | 135,400 | $977,588 |
| 2025-12-12 | Barbara-Jean A Bormann-Kennedy | Sell | $7.09 | 15,000 | $106,350 |
| 2025-12-01 | Beth Hecht | Sell | $7.01 | 16,667 | $116,836 |
| 2025-11-13 | John Patrick Shannon Jr | Sell | $7.46 | 23,242 | $173,385 |
| 2025-11-11 | Beth Hecht | Sell | $7.40 | 16,667 | $123,336 |
| 2025-09-11 | Marla Persky | Sell | $7.72 | 15,500 | $119,660 |
| 2025-08-28 | Jeffrey W Sherman | Sell | $7.92 | 42,232 | $334,477 |
| 2025-08-13 | John Johnson | Sell | $7.32 | 107,500 | $786,900 |
| 2025-08-12 | Dawn Halkuff | Sell | $7.28 | 42,500 | $309,400 |
| 2025-06-13 | Kevin Mcculloch | Buy | $4.38 | 25,000 | $109,500 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
XERS shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns XERS
Institutional investors own 60.6% of Xeris Biopharma's shares and insiders 3.03%. The largest holder is BlackRock Inc with 7.97% of the shares (14.5M), as of June 30, 2026. Among the top 20 institutions, 14 added shares and 6 reduced their stake in the latest filings. Short interest is 4.08% of the float, or 2.45 days of average trading volume. The share count rose 3,028.1% since 2016.
Related: XERS analyst forecast, XERS key metrics. See the XERS stock overview for the latest quote and news.
XERS ownership FAQ
Who owns the most Xeris Biopharma stock?
The largest shareholders of Xeris Biopharma are BlackRock Inc (7.97%), D. E. Shaw & Co LP (4.28%), Vanguard Capital Management, LLC (4.03%), State Street Corp (2.64%), Geode Capital Management, LLC (2.59%).
What percentage of Xeris Biopharma is owned by institutions?
Institutions hold 60.6% of Xeris Biopharma's shares outstanding; insiders hold 3.03%.
Which funds own Xeris Biopharma?
The largest fund holders of Xeris Biopharma are Vanguard MStar Total Stk Mkt Idx Invest (2.85%), iShares Russell 2000 ETF (2.42%), CREF Total Global Stock Account R3 (1.12%), Fidelity Small Cap Index (1.02%), iShares Russell 2000 Growth ETF (0.88%).
What is Xeris Biopharma's short interest?
7.2M shares of Xeris Biopharma were sold short, 4.08% of the float; at the average daily volume it would take 2.45 days to cover.
Are insiders buying or selling Xeris Biopharma?
Of the latest 17 reported insider transactions in Xeris Biopharma (since June 13, 2025), 1 were purchases and 16 were sales.
How many shares of Xeris Biopharma are outstanding?
Xeris Biopharma has 182.3M shares outstanding, of which 176.1M are in the public float.